An experimental Ebola vaccine will soon enter phase one of a clinical trial on humans, the National Institute of Health said Thursday.
Initial testing will take place at the NIH’s Clinical Center in Bethesda, Maryland, while the NIH is in the process of working out tests in Ebola-stricken West Africa. The vaccine was developed by the National Institute of Allergy and Infectious Diseases (NIAID) along with top pharmaceutical company GlaxoSmithKline. The NIH will soon launch other phase one trials of this vaccine as well as another developed by Canada’s Public Health Agency.
The NIAID/GSK vaccine will be tested in a small number of healthy adults who do not have the Ebola virus to see if their bodies create an immune response. The vaccine has already been successfully tested on monkeys.
Here’s how the vaccine works: When a study participant receives the vaccine, one part of the Ebola virus’ genetic material…
View original post 130 more words